News

Today, 150 years later, what has come to be known as the University of Illinois Eye & Ear Infirmary continues to strive for excellence in medical education, care and treatment of patients, and cutting-edge research.

The federal government has allotted $4 million for peer-reviewed vision research via the fiscal year 2009 (FY2009) defense appropriations.

History-taking is a little more time-consuming for cataract surgeons with the recent FDA approval of silodosin capsules (Rapaflo, Watson) for the treatment of symptoms due to benign prostatic hyperplasia.

Inspire Pharmaceuticals Inc. has initiated a phase I clinical trial of INS117548 ophthalmic solution for the treatment of glaucoma.

Allergan Inc. has introduced an over-the-counter artificial tear (Optive Sensitive Preservative-Free Lubricant Eye Drops) for patients who have dry eye or dryness following LASIK.

The FDA has granted premarket approval to a new pachymeter/auto-refractor/keratometer (PARK 1, Oculus).

David F. Williams, MD, MBA, has been named president of the American Society of Retina Specialists (ASRS).

Clinical trials provide far more information than just the safety and efficacy of a treatment. Information about the natural course and the risk factors of the disease can be gathered. Of equal importance is the collaboration of clinical investigators as they develop and carry out protocols facilitates incorporation of new ideas into medical practice.

Neil M. Bressler, MD, Susan B. Bressler, MD, Alexander J. "Sandy" Brucker, MD, and Stanley Chang, MD, were honored for their work in the subspecialty of retina Oct. 12 at the annual meeting of the American Society of Retina Specialists (ASRS).

Collagen cross-linking, the newest advancement in the refractive arena, possibly will stabilize keratoconic and ectatic corneas. LASIK, an area that always is improving, has seen changes in flap sizes and lasers. Knowledge of corneal biomechanics also is progressing to provide more information than ever before with new instrumentation. The phakic IOL market has expanded considerably, catering to those with high myopia. IOL options for pseudophakia also are expanding, and refractive lens exchange remains popular for hyperopia. In addition, questions of patient satisfaction postLASIK are being answered by an FDA task force.

Sleep disorders can be indicators of various unrecognized eye disorders, according to the results of a literature search reported in the November issue of Mayo Clinic Proceedings.

Optonol announced in a prepared statement that its proprietary mini glaucoma shunt (Ex-PRESS) will be paid under a new ambulatory payment classification (APC) beginning Jan. 1, 2009.

ISTA Pharmaceuticals has filed a new drug application (NDA) with the FDA for bepotastine ophthalmic solution (Bepreve). If approved, the solution would be used as an eye drop treatment for ocular itching associated with allergic conjunctivitis.

The American Academy of Ophthalmology (AAO) 2008 joint meeting with the European Society of Ophthalmology, held in Atlanta Nov. 8 to 11, featured strong attendance numbers. Preliminary figures for attendance at the meeting were approximately 22,000, and attendance at the Subspecialty Day events Nov. 7 and 8 totaled more than 6,200.

Prevent Blindness America (PBA) announced it has been awarded a 3-year cooperative agreement from the Centers for Disease Control and Prevention (CDC), with a first-year grant of $1 million.

Once you get employees to realize that their success or failure ultimately is up to them, the pressure is off you as a manager. The pressure is squarely in the place it needs to be: on the employees. Your only job then becomes augmenting their growth with the tools they need to be the hardest-working technicians you ever will have.

Children who have convergence insufficiency (CI) will respond better to weekly treatment sessions with a trained vision therapist than to a strictly home-based eye exercise program, according to a study released by the National Institutes of Health (NIH).

Determining the optimal size for an optical dispensary will allow the practice to obtain the highest return on investment and return on assets. The optimal size can be calculated in one of two ways. The first is to determine the number of dollars each square foot of space can generate. The second method is to calculate the percentage of total practice revenues the dispensary represents. Whichever method is used, remember the general rule for dispensary size: "bigger is better."

Visual merchandising is the art of displaying merchandise to encourage sales. Dispensing ophthalmology practices can create eye-catching displays by following some simple rules. Grouping frames by price point and brand helps to organize options for the customer. Displays can highlight individual brands through repetition, a pyramid design, using odd, rather than even numbers of items, considering the texture of background materials, and more.

The Optical Laboratories Association (OLA) inducted 12 industry veterans into the OLA Hall of Fame 2008.

Intercast Europe has made Augen Optics an authorized distributor of NXT Rx performance sunlenses. Intercast is a business of PPG Industries.

Carl Zeiss Meditec and Optovue announced that they have resolved their legal disputes pending in the Northern District of California and in Massachusetts Superior Court.

The novel technology found at the heart of an adaptive optics flood illumination fundus camera (AOFIFC, INOVEO)-an electromagnetic deformable mirror (Mirao 52-e, Imagine Eyes)-is designed to facilitate the acquisition of even higher resolution images than those captured by optical coherence tomography systems.

Both subjective and objective evaluation of diabetic macular edema (DME) can produce good results. In a recent study, the initial results of objective evaluation with retinal imaging technology (Heidelberg Retina Tomograph Retina Module, Heidelberg Engineering) showed good sensitivity and moderate specificity, whereas subjective evaluation by two expert assessors produced high sensitivity and specificity. Nevertheless, with optimization, the results of the two forms of evaluation became more evenly matched, suggesting that the retinal imaging technology can aid clinicians in detecting DME.

1-year results from the HORIZON open-label extension study of ranibizumab (Lucentis, Genentech) for the treatment of exudative age-related macular degeneration show that treatment beyond 2 years relatively is safe and well tolerated, but previously treated patients who received ranibizumab monthly for 2 years may be susceptible to loss of vision with less-frequent dosing during the third year of treatment.

A novel gene therapy approach for the treatment of a type of inherited retinal disease appears to be safe and effective in initial trials. Results offer hope for the treatment of a gamut of eye diseases that once were thought to be untreatable, according to one researcher.

In a dose-ranging phase IIb study, microplasmin 125 micrograms (ThromboGenics) was safe and demonstrated significant efficacy compared with placebo for inducing posterior vitreous detachment in eyes with macular holes or macular edema related to vitreomacular traction. Pivotal phase III trials are being planned.

Adjuvant use of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) with ranibizumab (Lucentis, Genentech) reduced the reduced the number of ranibizumab injections needed to control choroidal neovascularization secondary to age-related macular degeneration. Use of the two drugs together resulted in better visual acuity outcomes than those achieved with ranibizumab alone.

Visual acuity gains occurring in a 12-week, fixed-dose period were maintained throughout the 52-week trial of a novel agent (VEGF Trap-Eye, Regeneron Pharmaceuticals) for neovascular age-related macular degeneration. During the 9-month, as-needed dosing phase, the mean number of injections for all patients was two, and gains in visual acuity of up to nine letters were reported.

When data were analyzed from 25 patients who reached the 18-month visit in a phase II trial evaluating epiretinal brachytherapy (EpiRad90 Ophthalmic System, NeoVista) with bevacizumab (Avastin, Genentech), they demonstrated that the novel combination was associated with a significant gain in vision, an acceptable safety profile, and with minimal need for additional anti-VEGF treatment beyond an initial two injections.